Physician profile
David L Grice
NPI 1538279237
$19,881.24
in general payments reported to CMS, 2019-2025
29 companies · $5,296 in 2025
The $5,296 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,861 · 2020: $1,055 · 2021: $1,627 · 2022: $2,366 · 2023: $2,782 · 2024: $4,894 · 2025: $5,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,589 · Consulting Fee: $3,088 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,589.26 |
| Consulting Fee | $3,087.50 |
| Education | $295.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,194.15 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $2,402.26 | 2019-2025 | |
| Ucb, INC. | $1,160.91 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $1,134.84 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,046.41 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $934.17 | 2022-2025 | Sotyktu |
| Amgen INC. | $902.11 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $883.55 | 2020-2025 | |
| Leo Pharma INC. | $873.82 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $769.65 | 2022-2024 | Vtama |
| Pfizer INC. | $570.90 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $567.47 | 2023-2025 | Zoryve |
| Incyte Corporation | $542.91 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $489.37 | 2020-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $438.73 | 2019-2024 | Arazlo, Targretin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $346.71 | 2019-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $275.70 | 2019-2023 | Ilumya |
| Novartis Pharmaceuticals Corporation | $270.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.49 | 2023-2024 | Spevigo |
| Celgene Corporation | $184.32 | 2019 | |
| Janssen Scientific Affairs, LLC | $167.10 | 2021-2025 | Tremfya |
| Kyowa Kirin, INC. | $115.10 | 2024 | Poteligeo |
| Epi Health, LLC | $100.00 | 2022 | |
| Dermira, INC. | $99.06 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $80.86 | 2021-2022 | |
| Botanix Sb INC | $47.99 | 2025 | Sofdra |
| Lnhc, INC | $18.77 | 2025 | Zelsuvmi |
| Tempus Ai, INC | $16.24 | 2024 | Merlin Test |
| Organon LLC | $4.39 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.